Coronavirus Disease-2019 (COVID-19), driven by the SARS-CoV-2 virus, has disproportionately affected the elderly, with comorbidities like sarcopenia worsening prognosis. Considering the significant impact of RNA vaccines on survival rates in this population, our objective is to investigate the impact of vaccination on the survival of hospitalized elderly patients with COVID-19, considering the presence or absence of sarcopenia. Prospective study conducted on 159 patients aged>65 years from September 2021 to March 2022. Data about clinical and body composition, and mortality at 12-months after discharge were recorded. Sarcopenia was diagnosed according to the 2019 European Consensus criteria. At the twelfth month post-discharge, vaccinated sarcopenic individuals exhibited a mortality risk similar to vaccinated non-sarcopenic individuals, and lower than unvaccinated non-sarcopenic patients. Cox regression analysis, adjusted for age, gender, comorbidity, functional and vaccinal status, showed that the presence of sarcopenia did not significantly impact the risk of death within 12-months post-discharge. Vaccination emerges as a protective measure for sarcopenic patients, countering the potential adverse effects of sarcopenia on COVID-19 outcomes, underscoring the importance of immunization in the frail elderly with a call for meticulous monitoring of its benefits. Our study represents the first attempt to analyze the vaccine's effect on survival in sarcopenic hospitalized older adults with COVID-19. The administration of vaccination to sarcopenic patients proves pivotal, as its omission could lead to notably unfavorable outcomes within this specific population.

中文翻译：

---

肌肉减少症患者“平衡”：COVID-19 疫苗接种对死亡率的影响

由 SARS-CoV-2 病毒驱动的 2019 冠状病毒病 (COVID-19) 对老年人的影响尤为严重，肌肉减少症等合并症使预后恶化。考虑到 RNA 疫苗对该人群生存率的重大影响，我们的目标是研究疫苗接种对住院老年 COVID-19 患者生存的影响，考虑是否存在肌少症。2021年9月至2022年3月，对159名年龄>65岁的患者进行了前瞻性研究。记录了出院后12个月的临床和身体成分以及死亡率数据。肌肉减少症根据2019年欧洲共识标准诊断。出院后第十二个月，接种疫苗的肌肉减少症患者表现出与接种疫苗的非肌肉减少症患者相似的死亡风险，并且低于未接种疫苗的非肌肉减少症患者。根据年龄、性别、合并症、功能和疫苗状况进行调整后的 Cox 回归分析表明，肌少症的存在并未显着影响出院后 12 个月内的死亡风险。疫苗接种成为肌肉减少症患者的一种保护措施，可对抗肌肉减少症对 COVID-19 结果的潜在不利影响，强调免疫接种对体弱老年人的重要性，并呼吁对其益处进行仔细监测。我们的研究首次尝试分析疫苗对患有肌肉减少症的住院老年人 COVID-19 的生存影响。事实证明，对肌肉减少症患者接种疫苗至关重要，因为疏忽可能会导致该特定人群出现明显不利的结果。